A second approach was to understand why some tumor cells exhibited a rapid death response after erlotinib or gefitinib exposure, whilst other tumor cells, expressing equal protein amounts of ERBB1, were relatively insensitive to the drugs. This evidence concerns the gene EGFR and neoplasm.